Savant Capital, LLC Mersana Therapeutics, Inc. Transaction History
Savant Capital, LLC
- $13.2 Billion
- Q1 2025
A detailed history of Savant Capital, LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Savant Capital, LLC holds 111,141 shares of MRSN stock, worth $40,010. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111,141Holding current value
$40,010% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MRSN
# of Institutions
132Shares Held
101MCall Options Held
77.2KPut Options Held
453K-
Nextech Invest Ag12.1MShares$4.34 Million3.22% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$4.08 Million0.76% of portfolio
-
Vr Adviser, LLC New York, NY10.3MShares$3.69 Million2.42% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$3.12 Million3.35% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$3.02 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $35M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...